C3N-01408
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 58.2642026
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.430
- CHOLESTEROL_HOMEOSTASIS+0.340
- ANGIOGENESIS+0.330
- XENOBIOTIC_METABOLISM+0.330
- INFLAMMATORY_RESPONSE+0.310
- COMPLEMENT+0.300
- KRAS_SIGNALING_UP+0.270
- ADIPOGENESIS+0.260
- GLYCOLYSIS+0.260
- BILE_ACID_METABOLISM+0.250
Top 10 suppressed
- G2M_CHECKPOINT-0.410
- WNT_BETA_CATENIN_SIGNALING-0.380
- E2F_TARGETS-0.360
- MYC_TARGETS_V1-0.330
- MYC_TARGETS_V2-0.260
- UNFOLDED_PROTEIN_RESPONSE-0.260
- SPERMATOGENESIS-0.190
- APICAL_SURFACE-0.170
- MITOTIC_SPINDLE-0.170
- UV_RESPONSE_DN-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518286 | — | F | 0.840 |
| 2 | TCGA-97-8177-01A-11R-2287-07 | — | cohortA1 | 0.829 |
| 3 | TCGA-67-3772-01A-01R-0946-07 | — | cohortA1 | 0.824 |
| 4 | TCGA-05-4403-01A-01R-1206-07 | — | cohortA1 | 0.811 |
| 5 | SJEPD013_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.806 |
| 6 | SRR5088897 | — | — | 0.800 |
| 7 | AUR-AFE9-TTM4-A-1-1-R-A742-41 | — | C | 0.798 |
| 8 | d2bd30d9-e0ce-4b80-889b-974bc0563d9c | — | — | 0.796 |
| 9 | TCGA-AC-A62Y-01A-11R-A29R-07 | — | A | 0.795 |
| 10 | BS_FJZPQZ2C | pleomorphic xanthoastrocytoma(PXA) | — | 0.794 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.180 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.180 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.170 | Remibrutinib | — uncovered |